Article Text

Download PDFPDF

674 IMMUNOCERV, an ongoing phase II trial combining PDS0101, an HPV-specific T cell immunotherapy, with chemotherapy and radiation for treatment of locally advanced cervical cancers
  1. Kyoko Yoshida-Court,
  2. Olsi Gjyshi,
  3. Madison O’Hara,
  4. Lilie Lin,
  5. Anuja Jhingran,
  6. Melissa Joyner,
  7. Tatiana Cisneros Napravnik,
  8. Erica Lynn,
  9. Lauren Colbert,
  10. Jagannadha K Sastry and
  11. Ann Klopp
  1. MD Anderson Cancer Center, Houston, TX, USA


Background Human Papillomavirus (HPV) cancers are uniquely antigenic with a ubiquitous and essential expression of the viral proteins E6 and E7. Radiation therapy is essential in treating locally advanced HPV-associated cancers, including cervical cancers. Radiation therapy (RT) may synergize with immunotherapy to stimulate T-cell mediated anti-tumor affects by increasing T-cell flux in tumors and promoting pathways that result in increased antigen presentation. To evaluate this, we are conducting a single-arm phase II trial combining PDS0101, an E6/7 HPV16 T-cell activating immunotherapy delivered subcutaneously, combined with the standard of care chemoradiation for patients with locally advanced squamous cell cervical cancer with either lymph node metastasis or tumors of >5 cm.

Methods 17 patients of a planned 35 have enrolled in the study. Patients receive 5 doses of PDS0101 starting 10 days before RT, then on Days 7, 28, and 49 (± 5 days) during the 7-week course of treatment and again after chemoradiation is complete at Day 170 (± 14 days). To date, eight patients have completed treatment and were evaluated with a post-treatment Positron Emission Tomography (PET) scan to assess the response. Tumor specimens were collected at baseline and end of treatment and were evaluated for changes in T-cell activation.

Results Seven of 8 patients (87.5%) enrolled on IMMUNOCERV demonstrated a complete response (CR) on PET at 3 months. For comparison, 40 of 54 (74.1%) patients treated on a prospective tissue collection protocol with standard of care chemoradiation had a CR on PET after 3 months. The observed 1-year disease-free survival rate for IMMUNOCERV patients is 85.7%, and the 1-year overall survival is 100%. The percentage of polyfunctional CD8+ T-cells expressing granzyme B and Ki67 increased from baseline to end of treatment (38.5% vs. 65.4%, p = 0.0253). There were also enhanced signals in the single function CD8+ T-cells (granzyme B, Ki67, and CD69). However, there were no significant changes in these markers for patients treated with a prospective tissue collection protocol. Toxicity attributable to PDS0101 included self-limited Grade 1 and 2 local injection site reactions in 7 patients (3 Grade 1 and 4 Grade 2).

Conclusions In an ongoing trial, PDS0101 HPV-specific immunotherapy is safe and well tolerated in combination with chemoradiation. The combination treatment appears to result in an expansion of intratumoral activated T-cells expressing granzyme B. Further analysis will determine if the combination results in sufficiently high disease-free survival rates in patients with locally advanced cervical cancer.

Acknowledgements We thank PDS biotechnology (Dr. F. Bedu-Addo, Dr. L. Wood) for providing PDS0101.

Trial Registration NCT04580771

Ethics Approval All patients were enrolled under a protocol approved by the UT M.D. Anderson Cancer Center Institutional Review Board (MDACC 2019–1260) and written informed consent were obtained from all patients.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.